194 related articles for article (PubMed ID: 24714650)
1. Pharmacological targeting of the β-amyloid precursor protein intracellular domain.
Branca C; Sarnico I; Ruotolo R; Lanzillotta A; Viscomi AR; Benarese M; Porrini V; Lorenzini L; Calzà L; Imbimbo BP; Ottonello S; Pizzi M
Sci Rep; 2014 Apr; 4():4618. PubMed ID: 24714650
[TBL] [Abstract][Full Text] [Related]
2. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
3. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Imbimbo BP; Hutter-Paier B; Villetti G; Facchinetti F; Cenacchi V; Volta R; Lanzillotta A; Pizzi M; Windisch M
Br J Pharmacol; 2009 Mar; 156(6):982-93. PubMed ID: 19239474
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Imbimbo BP; Del Giudice E; Cenacchi V; Volta R; Villetti G; Facchinetti F; Riccardi B; Puccini P; Moretto N; Grassi F; Ottonello S; Leon A
Pharmacol Res; 2007 Apr; 55(4):318-28. PubMed ID: 17292621
[TBL] [Abstract][Full Text] [Related]
5. The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.
Lanzillotta A; Sarnico I; Benarese M; Branca C; Baiguera C; Hutter-Paier B; Windisch M; Spano P; Imbimbo BP; Pizzi M
J Mol Neurosci; 2011 Sep; 45(1):22-31. PubMed ID: 21181298
[TBL] [Abstract][Full Text] [Related]
6. Major carboxyl terminal fragments generated by γ-secretase processing of the Alzheimer amyloid precursor are 50 and 51 amino acids long.
Pinnix I; Ghiso JA; Pappolla MA; Sambamurti K
Am J Geriatr Psychiatry; 2013 May; 21(5):474-83. PubMed ID: 23570890
[TBL] [Abstract][Full Text] [Related]
7. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
Weggen S; Eriksen JL; Sagi SA; Pietrzik CU; Golde TE; Koo EH
J Biol Chem; 2003 Aug; 278(33):30748-54. PubMed ID: 12777371
[TBL] [Abstract][Full Text] [Related]
8. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
Sivilia S; Lorenzini L; Giuliani A; Gusciglio M; Fernandez M; Baldassarro VA; Mangano C; Ferraro L; Pietrini V; Baroc MF; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Calzà L; Giardino L
BMC Neurosci; 2013 Apr; 14():44. PubMed ID: 23560952
[TBL] [Abstract][Full Text] [Related]
9. CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro.
Ronsisvalle N; Di Benedetto G; Parenti C; Amoroso S; Bernardini R; Cantarella G
Curr Alzheimer Res; 2014; 11(7):714-24. PubMed ID: 24938499
[TBL] [Abstract][Full Text] [Related]
10. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway.
Belyaev ND; Kellett KA; Beckett C; Makova NZ; Revett TJ; Nalivaeva NN; Hooper NM; Turner AJ
J Biol Chem; 2010 Dec; 285(53):41443-54. PubMed ID: 20961856
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
12. APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer's disease mutations.
Bergman A; Religa D; Karlström H; Laudon H; Winblad B; Lannfelt L; Lundkvist J; Näslund J
Exp Cell Res; 2003 Jul; 287(1):1-9. PubMed ID: 12799176
[TBL] [Abstract][Full Text] [Related]
13. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
14. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
Porrini V; Lanzillotta A; Branca C; Benarese M; Parrella E; Lorenzini L; Calzà L; Flaibani R; Spano PF; Imbimbo BP; Pizzi M
Neuroscience; 2015 Aug; 302():112-20. PubMed ID: 25450955
[TBL] [Abstract][Full Text] [Related]
15. Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease.
Bukhari H; Glotzbach A; Kolbe K; Leonhardt G; Loosse C; Müller T
Prog Neurobiol; 2017 Sep; 156():189-213. PubMed ID: 28587768
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
17. The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease.
Zhou ZD; Chan CH; Ma QH; Xu XH; Xiao ZC; Tan EK
Cell Adh Migr; 2011; 5(4):280-92. PubMed ID: 21785276
[TBL] [Abstract][Full Text] [Related]
18. Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment.
Flammang B; Pardossi-Piquard R; Sevalle J; Debayle D; Dabert-Gay AS; Thévenet A; Lauritzen I; Checler F
J Alzheimers Dis; 2012; 30(1):145-53. PubMed ID: 22406447
[TBL] [Abstract][Full Text] [Related]
19. Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to βγ-Secretase-Mediated Processing of the Amyloid-β Protein Precursor: Utility of an AβPP-GAL4 Reporter Assay.
Law BM; Guest AL; Pullen MWJ; Perkinton MS; Williams RJ
J Alzheimers Dis; 2018; 61(2):673-688. PubMed ID: 29254083
[TBL] [Abstract][Full Text] [Related]
20. Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production.
Gerber H; Wu F; Dimitrov M; Garcia Osuna GM; Fraering PC
J Biol Chem; 2017 Mar; 292(9):3751-3767. PubMed ID: 28096459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
